See the DrugPatentWatch profile for cosentyx

Based on the information available, there is no specific vaccination schedule recommended in conjunction with the use of Cosentyx (secukinumab). Cosentyx is a medication used to treat several conditions, including plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis. It is a type of drug known as a monoclonal antibody, which works by targeting and blocking a specific protein in the body (interleukin-17A) that is believed to play a role in inflammation and the symptoms of these conditions.

When it comes to vaccinations, the Centers for Disease Control and Prevention (CDC) recommends that individuals stay up-to-date on all recommended vaccines, unless there are specific contraindications or precautions. This includes both inactivated vaccines (those that do not contain live viruses or bacteria) and live vaccines. However, it is generally recommended that live vaccines be given at least 2 weeks before starting immunosuppressive therapy, such as Cosentyx, or at least 4 weeks after discontinuing such therapy [1].

It is important to note that the manufacturer of Cosentyx (Novartis) recommends that live vaccines be avoided during treatment with Cosentyx, and that patients should be up-to-date on all recommended vaccinations prior to starting treatment [2].

In summary, while there is no specific vaccination schedule recommended in conjunction with Cosentyx, it is important for individuals to stay up-to-date on all recommended vaccinations, and to discuss any vaccination plans with their healthcare provider prior to starting or stopping treatment with Cosentyx.

Sources:
[1] Centers for Disease Control and Prevention. (2021). Vaccination of persons with altered immunocompetence. In: Recommendations of the Advisory Committee on Immunization Practices (ACIP). <https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/immunocompetence.html>
[2] Novartis Pharmaceuticals Corporation. (2021). Cosentyx (secukinumab) [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corporation. <https://www.novartis.us/sites/www.novartis.us/files/cosentyx.pdf>
[3] DrugPatentWatch. (2021). Cosentyx (secukinumab) patents. <https://www.drugpatentwatch.com/drugs/cosentyx>